Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Quantitative Contribution of Six Major Transporters to the Hepatic Uptake of Drugs: "SLC-Phenotyping" Using Primary Human Hepatocytes.

Bi YA, Costales C, Mathialagan S, West M, Eatemadpour S, Lazzaro S, Tylaska L, Scialis R, Zhang H, Umland J, Kimoto E, Tess DA, Feng B, Tremaine LM, Varma MVS, Rodrigues AD.

J Pharmacol Exp Ther. 2019 Jul;370(1):72-83. doi: 10.1124/jpet.119.257600. Epub 2019 Apr 11.

PMID:
30975793
2.

Effect of Hepatic Organic Anion-Transporting Polypeptide 1B Inhibition and Chronic Kidney Disease on the Pharmacokinetics of a Liver-Targeted Glucokinase Activator: A Model-Based Evaluation.

Bergman A, Bi YA, Mathialagan S, Litchfield J, Kazierad DJ, Pfefferkorn JA, Varma MVS.

Clin Pharmacol Ther. 2019 Oct;106(4):792-802. doi: 10.1002/cpt.1419. Epub 2019 Apr 8.

PMID:
30919935
3.

Human Pluripotent Stem Cell-Derived Kidney Model for Nephrotoxicity Studies.

Bajaj P, Rodrigues AD, Steppan CM, Engle SJ, Mathialagan S, Schroeter T.

Drug Metab Dispos. 2018 Nov;46(11):1703-1711. doi: 10.1124/dmd.118.082727. Epub 2018 Aug 31.

PMID:
30171163
4.

Organic Anion Transporter 2-Mediated Hepatic Uptake Contributes to the Clearance of High-Permeability-Low-Molecular-Weight Acid and Zwitterion Drugs: Evaluation Using 25 Drugs.

Kimoto E, Mathialagan S, Tylaska L, Niosi M, Lin J, Carlo AA, Tess DA, Varma MVS.

J Pharmacol Exp Ther. 2018 Nov;367(2):322-334. doi: 10.1124/jpet.118.252049. Epub 2018 Aug 22.

PMID:
30135178
5.

Optimization of Metabolic and Renal Clearance in a Series of Indole Acid Direct Activators of 5'-Adenosine Monophosphate-Activated Protein Kinase (AMPK).

Edmonds DJ, Kung DW, Kalgutkar AS, Filipski KJ, Ebner DC, Cabral S, Smith AC, Aspnes GE, Bhattacharya SK, Borzilleri KA, Brown JA, Calabrese MF, Caspers NL, Cokorinos EC, Conn EL, Dowling MS, Eng H, Feng B, Fernando DP, Genung NE, Herr M, Kurumbail RG, Lavergne SY, Lee EC, Li Q, Mathialagan S, Miller RA, Panteleev J, Polivkova J, Rajamohan F, Reyes AR, Salatto CT, Shavnya A, Thuma BA, Tu M, Ward J, Withka JM, Xiao J, Cameron KO.

J Med Chem. 2018 Mar 22;61(6):2372-2383. doi: 10.1021/acs.jmedchem.7b01641. Epub 2018 Feb 28.

PMID:
29466005
6.

Role of Hepatic Organic Anion Transporter 2 in the Pharmacokinetics of R- and S-Warfarin: In Vitro Studies and Mechanistic Evaluation.

Bi YA, Lin J, Mathialagan S, Tylaska L, Callegari E, Rodrigues AD, Varma MVS.

Mol Pharm. 2018 Mar 5;15(3):1284-1295. doi: 10.1021/acs.molpharmaceut.7b01108. Epub 2018 Feb 20.

PMID:
29433307
7.

Organic Anion Transporter 2 Mediates Hepatic Uptake of Tolbutamide, a CYP2C9 Probe Drug.

Bi YA, Mathialagan S, Tylaska L, Fu M, Keefer J, Vildhede A, Costales C, Rodrigues AD, Varma MVS.

J Pharmacol Exp Ther. 2018 Mar;364(3):390-398. doi: 10.1124/jpet.117.245951. Epub 2018 Jan 11.

PMID:
29326367
8.

In vitro studies with two human organic anion transporters: OAT2 and OAT7.

Mathialagan S, Costales C, Tylaska L, Kimoto E, Vildhede A, Johnson J, Johnson N, Sarashina T, Hashizume K, Isringhausen CD, Vermeer LMM, Wolff AR, Rodrigues AD.

Xenobiotica. 2018 Oct;48(10):1037-1049. doi: 10.1080/00498254.2017.1384595. Epub 2017 Oct 13.

PMID:
28945155
9.

Transporter-Mediated Disposition, Clinical Pharmacokinetics and Cholestatic Potential of Glyburide and Its Primary Active Metabolites.

Li R, Bi YA, Vildhede A, Scialis RJ, Mathialagan S, Yang X, Marroquin LD, Lin J, Varma MVS.

Drug Metab Dispos. 2017 Jul;45(7):737-747. doi: 10.1124/dmd.116.074815. Epub 2017 Apr 24.

PMID:
28438781
10.

Evaluation of Renal Transporter Inhibition Using Creatinine as a Substrate In Vitro to Assess the Clinical Risk of Elevated Serum Creatinine.

Mathialagan S, Rodrigues AD, Feng B.

J Pharm Sci. 2017 Sep;106(9):2535-2541. doi: 10.1016/j.xphs.2017.04.009. Epub 2017 Apr 14.

PMID:
28416419
11.

Erratum to: Reliable Rate Measurements for Active and Passive Hepatic Uptake Using Plated Human Hepatocytes.

Bi YA, Scialis RJ, Lazzaro S, Mathialagan S, Kimoto E, Keefer J, Zhang H, Vildhede AM, Costales C, Rodrigues AD, Tremaine LM, Varma MVS.

AAPS J. 2017 May;19(3):882. doi: 10.1208/s12248-017-0061-0. No abstract available.

PMID:
28233243
12.

Reliable Rate Measurements for Active and Passive Hepatic Uptake Using Plated Human Hepatocytes.

Bi YA, Scialis RJ, Lazzaro S, Mathialagan S, Kimoto E, Keefer J, Zhang H, Vildhede AM, Costales C, Rodrigues AD, Tremaine LM, Varma MVS.

AAPS J. 2017 May;19(3):787-796. doi: 10.1208/s12248-017-0051-2. Epub 2017 Feb 10. Erratum in: AAPS J. 2017 May;19(3):882.

PMID:
28188574
13.

Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach.

Mathialagan S, Piotrowski MA, Tess DA, Feng B, Litchfield J, Varma MV.

Drug Metab Dispos. 2017 Apr;45(4):409-417. doi: 10.1124/dmd.116.074294. Epub 2017 Feb 8.

PMID:
28179375
14.

Relationship between performance barriers and pharmacist competency towards the implementation of an expanded public health pharmacy role.

Mathialagan A, Nagalinggam P, Mathialagan S, Kirby BP.

Int J Pharm Pract. 2015 Oct;23(5):320-6. doi: 10.1111/ijpp.12170. Epub 2015 Jan 13.

PMID:
25582973
15.

Aminopyridinecarboxamide-based inhaled IKK-2 inhibitors for asthma and COPD: Structure-activity relationship.

Xie J, Poda GI, Hu Y, Chen NX, Heier RF, Wolfson SG, Reding MT, Lennon PJ, Kurumbail RG, Selness SR, Li X, Kishore NN, Sommers CD, Christine L, Bonar SL, Venkatraman N, Mathialagan S, Brustkern SJ, Huang HC.

Bioorg Med Chem. 2011 Feb 1;19(3):1242-55. doi: 10.1016/j.bmc.2010.12.027. Epub 2010 Dec 23.

PMID:
21236687
16.

Expression, purification and functional characterization of IkappaB kinase-2 (IKK-2) mutants.

Mathialagan S, Poda GI, Kurumbail RG, Selness SR, Hall T, Reitz BA, Weinberg RA, Kishore N, Mbalaviele G.

Protein Expr Purif. 2010 Aug;72(2):254-61. doi: 10.1016/j.pep.2010.02.009. Epub 2010 Feb 20.

PMID:
20176108
17.

Novel insights into the cellular mechanisms of the anti-inflammatory effects of NF-kappaB essential modulator binding domain peptides.

Baima ET, Guzova JA, Mathialagan S, Nagiec EE, Hardy MM, Song LR, Bonar SL, Weinberg RA, Selness SR, Woodard SS, Chrencik J, Hood WF, Schindler JF, Kishore N, Mbalaviele G.

J Biol Chem. 2010 Apr 30;285(18):13498-506. doi: 10.1074/jbc.M109.099895. Epub 2010 Feb 18.

18.

Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor.

Mbalaviele G, Pauley AM, Shaffer AF, Zweifel BS, Mathialagan S, Mnich SJ, Nemirovskiy OV, Carter J, Gierse JK, Wang JL, Vazquez ML, Moore WM, Masferrer JL.

Biochem Pharmacol. 2010 May 15;79(10):1445-54. doi: 10.1016/j.bcp.2010.01.003. Epub 2010 Jan 11.

PMID:
20067770
19.

Aminopyridinecarboxamide-based inhibitors: Structure-activity relationship.

Bonafoux DF, Bonar SL, Clare M, Donnelly AM, Glaenzer JL, Guzova JA, Huang H, Kishore NN, Koszyk FJ, Lennon PJ, Libby A, Mathialagan S, Oburn DS, Rouw SA, Sommers CD, Tripp CS, Vanella LJ, Weier R, Wolfson SG, Huang HC.

Bioorg Med Chem. 2010 Jan 1;18(1):403-14. doi: 10.1016/j.bmc.2009.10.040. Epub 2009 Oct 27.

PMID:
19914076
20.

Novel tight-binding inhibitory factor-kappaB kinase (IKK-2) inhibitors demonstrate target-specific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammation.

Sommers CD, Thompson JM, Guzova JA, Bonar SL, Rader RK, Mathialagan S, Venkatraman N, Holway VW, Kahn LE, Hu G, Garner DS, Huang HC, Chiang PC, Schindler JF, Hu Y, Meyer DM, Kishore NN.

J Pharmacol Exp Ther. 2009 Aug;330(2):377-88. doi: 10.1124/jpet.108.147538. Epub 2009 May 28.

PMID:
19478133
21.

A novel, highly selective, tight binding IkappaB kinase-2 (IKK-2) inhibitor: a tool to correlate IKK-2 activity to the fate and functions of the components of the nuclear factor-kappaB pathway in arthritis-relevant cells and animal models.

Mbalaviele G, Sommers CD, Bonar SL, Mathialagan S, Schindler JF, Guzova JA, Shaffer AF, Melton MA, Christine LJ, Tripp CS, Chiang PC, Thompson DC, Hu Y, Kishore N.

J Pharmacol Exp Ther. 2009 Apr;329(1):14-25. doi: 10.1124/jpet.108.143800. Epub 2009 Jan 23.

PMID:
19168710
22.

Inhibition of IKK-2 by 2-[(aminocarbonyl)amino]-5-acetylenyl-3-thiophenecarboxamides.

Bonafoux D, Bonar S, Christine L, Clare M, Donnelly A, Guzova J, Kishore N, Lennon P, Libby A, Mathialagan S, McGhee W, Rouw S, Sommers C, Tollefson M, Tripp C, Weier R, Wolfson S, Min Y.

Bioorg Med Chem Lett. 2005 Jun 2;15(11):2870-5.

PMID:
15911271
23.

A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts.

Kishore N, Sommers C, Mathialagan S, Guzova J, Yao M, Hauser S, Huynh K, Bonar S, Mielke C, Albee L, Weier R, Graneto M, Hanau C, Perry T, Tripp CS.

J Biol Chem. 2003 Aug 29;278(35):32861-71. Epub 2003 Jun 17.

24.

IKK-i and TBK-1 are enzymatically distinct from the homologous enzyme IKK-2: comparative analysis of recombinant human IKK-i, TBK-1, and IKK-2.

Kishore N, Huynh QK, Mathialagan S, Hall T, Rouw S, Creely D, Lange G, Caroll J, Reitz B, Donnelly A, Boddupalli H, Combs RG, Kretzmer K, Tripp CS.

J Biol Chem. 2002 Apr 19;277(16):13840-7. Epub 2002 Feb 11.

25.

Kinetic mechanisms of IkappaB-related kinases (IKK) inducible IKK and TBK-1 differ from IKK-1/IKK-2 heterodimer.

Huynh QK, Kishore N, Mathialagan S, Donnelly AM, Tripp CS.

J Biol Chem. 2002 Apr 12;277(15):12550-8. Epub 2002 Jan 28.

26.

Modulation of blood pressure in the Dahl SS/jr rat by embryo transfer.

Kubisch HM, Mathialagan S, Gómez-Sánchez EP.

Hypertension. 1998 Jan;31(1 Pt 2):540-5.

PMID:
9453359
27.

Simple sensitive solid-phase extraction of paraquat from plasma using cyanopropyl columns.

Smith NB, Mathialagan S, Brooks KE.

J Anal Toxicol. 1993 May-Jun;17(3):143-5.

PMID:
8336487

Supplemental Content

Loading ...
Support Center